HUNS001-01 / RAINBOW - LARVOL DELTA

INTRA-CEREBRAL AUTOLOGOUS MESENCHYMAL STROMAL CELL TRANSPLANTATION THERAPY FOR CHROMIC ISCHEMIC STROKE PATIENTS: PHASE 2A CLINICAL TRIAL (WSC 2025) - "The BMSC product, HUNS001 (4 x 10^7 cells) is administered around infarct area stereo-tactically... The study will evaluate safety and efficacy of intra-cerebral BMSC transplantation in chronic stroke patients. The results would provide critical data to further expand the eligibility of this therapy to a broader stroke population for future larger clinical trial."

Clinical • P2a data • Stroma • Cardiovascular • Ischemic stroke • Transplantation

Intracerebral Autologous Mesenchymal Stem Cell Transplantation Therapy for Patients with Ischemic Stroke in Chronic phase: Phase 2a clinical trial (ISC 2025) - "We determined the safety of autologous MSC product, HUNS001, when administered to acute ischemic stroke patients.We started the new project, RAINBOW-2a study on Oct...Each patient will be given a dose of 40 million cells. Neurological scoring, MRI, 18F-FDG PET, and 123I-Iomazenil SPECT are performed for 1 year after the administration."

Clinical • P2a data • Bone Marrow Transplantation • Cardiovascular • Ischemic stroke • Transplantation